This remains an actively moving area, however: on February 27, 2026, the HHS Secretary publicly announced an intent to move roughly 14 of the 19 Category 2-listed peptides, reportedly including ipamorelin and CJC-1295, back toward Category 1 status, and multiple industry and legal-news outlets reported further FDA action in the following months easing Category 2-related restrictions on this group of peptides
Beyond-Use Dates & Pharmacy Types Understanding 503A vs 503B pharmacies Beyond-Use Dates (BUDs) define the recommended window for using a compounded medication while maintaining optimal safety and effectiveness
Suppliers who provide independent third-party HPLC certificates, rather than in-house testing only, offer a higher degree of quality assurance relevant to research integrity
Listening to the patient and taking their reported symptoms seriously
The peptide demonstrates protective effects against gastric ulceration, promotes healing of intestinal lesions, and modulates gut inflammation through multiple pathways
Using normal saline instead of bacteriostatic water